|
Roche’s Rein on Tamiflu Data Raises Doubts About Drug’s Efficacy: BMJ
Roche’s claims that blockbuster influenza drug Tamiflu has reduced complications and hospital stays are not supported by clinical trial data, the FDA says as groups call for the company to release its trial findings.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
EMA Updates Postmarket Safety, Efficacy GuidanceEU: Include Variations When Submitting Marketing Authorization AmendmentsBalance Needed Between Clarity, Restrictions in EU Plan for Postauthorization Efficacy Studies: StakeholdersEU Plans for Postmarket Efficacy Studies Could Stifle Industry Innovation
|
Subscribe
Archives